Carcinoma, Bronchogenic

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer

Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)